Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

Contact Supplier

Jai Radhe Sales is your partner for all your sourcing needs.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

7 API Suppliers, 7 Listed Suppliers, $ API Reference Price

7 API Suppliers
7 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

22 Drugs in Development

22 Drugs in Development

FINISHED DOSAGE FORMULATIONS

2 FDF Dossiers, 2 Listed Dossiers

2 FDF Dossiers
2 Listed Dossiers

DIGITAL CONTENT

33 NEWS #PharmaBuzz

media
33 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions

globalSalesInformation
1 US Medicaid Prescriptions

MARKET PLACE

2 APIs

marketPlace
2 APIs

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

2,396,493

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: Daridorexant, 1505484-82-1, Act-541468, Quviviq, Daridorexant [usan], Lmq24g57e9

Molecular Formula

C₂₃H₂₃ClN₆O₂

Molecular Weight

450.9 g/mol

InChI Key

NBGABHGMJVIVBW-QHCPKHFHSA-N

FDA UNII

LMQ24G57E9

Nemorexant is under investigation in clinical trial NCT03101189 (A Study of ACT-541468 in Healthy Japanese and Caucasian Subjects).

Daridorexant is an Orexin Receptor Antagonist. The mechanism of action of daridorexant is as an Orexin Receptor Antagonist.

1 2D Structure

Daridorexant

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

[(2S)-2-(5-chloro-4-methyl-1H-benzimidazol-2-yl)-2-methylpyrrolidin-1-yl]-[5-methoxy-2-(triazol-2-yl)phenyl]methanone

2.1.2 InChI

InChI=1S/C23H23ClN6O2/c1-14-17(24)6-7-18-20(14)28-22(27-18)23(2)9-4-12-29(23)21(31)16-13-15(32-3)5-8-19(16)30-25-10-11-26-30/h5-8,10-11,13H,4,9,12H2,1-3H3,(H,27,28)/t23-/m0/s1

2.1.3 InChI Key

NBGABHGMJVIVBW-QHCPKHFHSA-N

2.1.4 Canonical SMILES

CC1=C(C=CC2=C1N=C(N2)C3(CCCN3C(=O)C4=C(C=CC(=C4)OC)N5N=CC=N5)C)Cl

2.1.5 Isomeric SMILES

CC1=C(C=CC2=C1N=C(N2)[C@@]3(CCCN3C(=O)C4=C(C=CC(=C4)OC)N5N=CC=N5)C)Cl

2.2 Other Identifiers

2.2.1 UNII

LMQ24G57E9

2.3 Synonyms

2.3.1 MeSH Synonyms

1. ((s)-(2-(5-chloro-4-methyl-1h-benzo(d)imidazol-2-yl)-2-methylpyrrolidin-1-yl) (5 Methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone)

2. Act-541468

3. Daridorexant

4. Methanone, ((2s)-2-(6-chloro-7-methyl-1h-benzimidazol-2-yl)-2-methyl-1-pyrrolidinyl)(5-methoxy-2-(2h-1,2,3-traizol-2-yl)phenyl)-

2.3.2 Depositor-Supplied Synonyms

1. Daridorexant

2. 1505484-82-1

3. Act-541468

4. Quviviq

5. Daridorexant [usan]

6. Lmq24g57e9

7. Act541468

8. [(2~{s})-2-(6-chloranyl-7-methyl-1~{h}-benzimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-[5-methoxy-2-(1,2,3-triazol-2-yl)phenyl]methanone

9. [(2s)-2-(5-chloro-4-methyl-1h-benzimidazol-2-yl)-2-methylpyrrolidin-1-yl]-[5-methoxy-2-(triazol-2-yl)phenyl]methanone

10. [(2s)-2-(5-chloro-4-methyl-1h-benzimidazol-2-yl)-2-methylpyrrolidin-1-yl][5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl]methanone

11. Methanone, ((2s)-2-(6-chloro-7-methyl-1h-benzimidazol-2-yl)-2-methyl-1-pyrrolidinyl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)-

12. Nemorexant (former Name)

13. Daridorexant [inn]

14. Unii-lmq24g57e9

15. Daridorexant [who-dd]

16. Chembl4297590

17. Schembl16766318

18. Gtpl11648

19. Bdbm334973

20. Dtxsid701336356

21. Nemorexant; Act-541468

22. Who 10679

23. Us9732075, Example 5.36

24. At32805

25. Db15031

26. Hy-109095

27. Cs-0039396

28. Act 541468;act-541468

29. (2s)-2-(5-chloro-4-methyl-1h-benzimidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone

30. (s)-(2-(5-chloro-4-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5 Methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone

31. (s)-2-(5-chloro-4-methyl-1h Benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl](5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone

32. [(s)-2-(5-chloro-4-methyl-1h-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methoxy-2-[1,2,3]triazol-2-yl-phenyl)-methanone

2.4 Create Date

2015-06-22

3 Chemical and Physical Properties

Molecular Formula	C₂₃H₂₃ClN₆O₂
Molecular Weight	450.9 g/mol
XLogP3	4.1
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	5
Rotatable Bond Count	4
Exact Mass	450.1571017 g/mol
Monoisotopic Mass	450.1571017 g/mol
Topological Polar Surface Area	88.9 Å²
Heavy Atom Count	32
Formal Charge	0
Complexity	693
Isotope Atom Count	0
Defined Atom Stereocenter Count	1
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Indication

Quviviq is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.

5 Pharmacology and Biochemistry

5.1 FDA Pharmacological Classification

5.1.1 Active Moiety

DARIDOREXANT

5.1.2 FDA UNII

LMQ24G57E9

5.1.3 Pharmacological Classes

Orexin Receptor Antagonists [MoA]; Orexin Receptor Antagonist [EPC]

5.2 ATC Code

N05

API SUPPLIERS

01

Inke S.A

Spain

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Rescon USA Summit

Exhibiting

Inke S.A: APIs manufacturing plant.

Contact Supplier

Spain

Virtual Booth

Digital Content

USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT

Product Web Link

02

FARMAK, a.s

Czech Republic

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

CPhI India 2024

Attending

Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

Contact Supplier

Czech Republic

Virtual Booth

Digital Content

USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT

03

Metrochem API Private Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Pharmtech & Ingredients

Exhibiting

Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

Contact Supplier

India

Virtual Booth

Digital Content

USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT

04

Moehs Iberica

Spain

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

CPhI WW Frankfurt

Booth #11.0C6

Moehs Group, a reference company in the production of pharmaceutical active ingredients.

Contact Supplier

Spain

Virtual Booth

Digital Content

USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT

05

Supriya Lifescience

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

CPhI India 2024

Booth #1.B20

Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.

Contact Supplier

India

Virtual Booth

Digital Content

USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT

06

Maithri Drugs

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

euroPLX 86 Munich

Not Confirmed

07

MSN Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

euroPLX 86 Munich

Not Confirmed

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

01

Inke S.A

Spain

Rescon USA Summit

Exhibiting

Inke S.A: APIs manufacturing plant.

Contact Supplier

Spain

Virtual Booth

Digital Content

Daridorexant

About the Company : Inke S.A., is focused since 1980 in the development and manufacture of the highest quality Active Pharmaceutical Ingredients (APIs) with complex synthesis processes for diverse the...

Inke S.A., is focused since 1980 in the development and manufacture of the highest quality Active Pharmaceutical Ingredients (APIs) with complex synthesis processes for diverse therapeutic areas, but mainly for use in Respiratory. Inke has been successfully inspected by every major global authority for a wide array of products (last inspection on behalf of US-FDA was in 2023). For the last two decades, the company has made strong strides to become a prestige provider of respiratory APIs for inhalation.

Product Web Link

02

FARMAK, a.s

Czech Republic

CPhI India 2024

Attending

Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

Contact Supplier

Czech Republic

Virtual Booth

Digital Content

Daridorexant

About the Company : Farmak, A.S. is a privately held chemical and pharmaceutical company based in the Czech Republic. It specializes in researching, developing and producing active pharmaceutical ingr...

Farmak, A.S. is a privately held chemical and pharmaceutical company based in the Czech Republic. It specializes in researching, developing and producing active pharmaceutical ingredients (APIs), intermediates and specialized chemicals. The company primarily focuses on exporting its products, with the main markets being the EU, USA, India, Japan and Latin America. Additionally, Farmak offers contract manufacturing and custom synthesis services through its R&D department to support the clients.

03

Metrochem API Private Limited

India

Pharmtech & Ingredients

Exhibiting

Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

Contact Supplier

India

Virtual Booth

Digital Content

Daridorexant

About the Company :

Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product ...

Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product groups and has been approved by ISO 9001-2015, USFDA, WHO GMP, Cofepris & Japanese authorities. Metrochem’s in-depth industry knowledge, & hi-tech & advanced infrastructure, helps it provide quality products to its customers. Note: None of the products will be supplied to the countries where this could conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer

04

Moehs Iberica

Spain

CPhI WW Frankfurt

Booth #11.0C6

Moehs Group, a reference company in the production of pharmaceutical active ingredients.

Contact Supplier

Spain

Virtual Booth

Digital Content

Daridorexant

About the Company : Since its founding in 1962, MOEHS has produced Active Pharmaceutical Ingredients (APIs) for the international pharmaceutical industry. Thanks to a business history of more than 50 ...

Since its founding in 1962, MOEHS has produced Active Pharmaceutical Ingredients (APIs) for the international pharmaceutical industry. Thanks to a business history of more than 50 years, MOEHS has considerable technical experience in the production of these substances. At Moehs Group we have a large tradition and experience in the area of manufacturing of active pharmaceutical and veterinary ingredients, agrochemicals, nutraceutical, cosmetic, as well as fine chemistry in general, with high levels of quality and safety standards-GMP´s, ICH, approved by the FDA and TGA.

05

Supriya Lifescience

India

CPhI India 2024

Booth #1.B20

Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.

Contact Supplier

India

Virtual Booth

Digital Content

Daridorexant

About the Company : Supriya Lifescience Ltd. specializes in API manufacturing, focusing on therapeutic segments like antihistamines, anti-allergic drugs, vitamins, anaesthetics and anti-asthmatics. Su...

Supriya Lifescience Ltd. specializes in API manufacturing, focusing on therapeutic segments like antihistamines, anti-allergic drugs, vitamins, anaesthetics and anti-asthmatics. Supriya follows industry standards and constantly improves to deliver quality products. Its facility is 47,000 square meters with dedicated areas for warehouse, QA, QC, R&D, production and finished products. The current capacity is 550 KL, with plans to expand to over 1000 KL by 2024. Supriya has 14 active USDMFs, 8 active CEPs, strong R&D and compliant facilities worldwide. Supriya works with innovators, generic companies, and as a CMO.